Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 2/20 | 0.41 |
| ▸ | F3 | P13726 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | KDM4B | O94953 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637911 | 0.86 | TNF (0.41) | KDM4CMAPTPDE5AIKBKETBK1 | |
| SCHEMBL1180188 | 0.78 | NPC1 (0.47) | MAPTIDO1DYRK1ANPC1GBA1 | |
| SCHEMBL1181806 | 0.71 | ACHE (0.41) | MAPTDYRK1ANPC1GBA1 | |
| SCHEMBL17967560 | 0.69 | FGFR1 (0.38) | NPC1GBA1 | |
| SCHEMBL1849192 | 0.68 | TOP1 (0.45) | MAPTNPC1GBA1 | |
| SCHEMBL17967674 | 0.67 | PDE5A (0.41) | MAPTF7F3F10PDE5A | |
| SCHEMBL4088326 | 0.66 | CHEK2 (0.44) | NPC1 | |
| SCHEMBL8566063 | 0.65 | ALDH1A1 (0.50) | MAPTPDE5ANPC1GSK3B | |
| SCHEMBL4718800 | 0.63 | CHEK2 (0.50) | — | |
| SCHEMBL14344501 | 0.62 | KDM4C (1.00) | KDM4CMAPTPDE5ANPC1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006316-B2 | 9H-pyrrolo-dipyridine derivatives | UCB Biopharma SRL (BE) | 2024-06-11 | — | — | US | disclosed |
| US-20220213103-A1 | 9H-PYRROLO-DIPYRIDINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-07-07 | — | — | US | disclosed |
| CN-110283134-B | Triazine benzene derivative and application thereof | 武汉尚赛光电科技有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-2828250-B1 | QUINAZOLINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2021-03-10 | — | — | EP | disclosed |
| EP-2513110-B1 | 1,7-DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2018-12-05 | — | — | EP | disclosed |
| US-9440976-B2 | 1,7-diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440976-B2 | 1,7-diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440976-B2 | 1,7-diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9216980-B2 | Methods of use of diazacarbazoles for treating cancer | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| WO-2011073263-A1 | 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073263-A1 | 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2300475-A1 | DIAZACARBAZOLES AND METHODS OF USE | Genentech, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2300475-A1 | DIAZACARBAZOLES AND METHODS OF USE | Genentech, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010109084-A2 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2009151598-A8 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009151598-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009151598-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213103-A1 | 9H-PYRROLO-DIPYRIDINE DERIVATIVES | MAPT, PSEN1, PRNP | KDM4C 2769/4885MAPT 1/4885F7 2925/4885 |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | KDM4C 717/4885MAPT 4241/4885F7 3657/4885 |
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | KDM4C 900/4885MAPT 3924/4885F7 3016/4885 |
| US-12006316-B2 | 9H-pyrrolo-dipyridine derivatives | MAPT, PSEN1, PRNP | KDM4C 2769/4885MAPT 1/4885F7 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.